An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
QUEST-1
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Treatment-naïve, Genotype 1 Hepatitis Cinfected Subjects
2 other identifiers
interventional
395
12 countries
62
Brief Summary
The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in participants who are infected with genotype 1 hepatitis C virus who have never received treatment before. Participants will also receive peginterferon alpha-2a and ribavirin as part of their treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Feb 2011
62 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 7, 2011
CompletedStudy Start
First participant enrolled
February 1, 2011
CompletedFirst Posted
Study publicly available on registry
February 4, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2013
CompletedResults Posted
Study results publicly available
June 4, 2014
CompletedJune 4, 2014
May 1, 2014
1.9 years
January 7, 2011
January 27, 2014
May 20, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)
The table below shows the percentage of participants in each treatment group who achieved a SVR12, defined as the percentage of participants with undetectable plasma Hepatitis C virus ribonucleic acid 12 weeks after planned end of treatment.
Week 36 or Week 60
Secondary Outcomes (33)
The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)
Week 72
The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)
Week 48 or Week 72
The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)
Week 28 or Week 52
Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
Day 3, Week 1, Week 4, Week 12, Week 24, and Week 48
Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
Day 3, Week 1, Week 4, Week 12, Week 24, and Week 48
- +28 more secondary outcomes
Study Arms (2)
TMC435
EXPERIMENTALTMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alpha-2a (PegIFN alpha-2a) and ribavirin (RBV) for 24 or 48 weeks
Placebo
PLACEBO COMPARATORPlacebo 150 mg capsule once daily for 12 weeks in addition to PegIFNα-2a and RBV for 48 weeks
Interventions
150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
Eligibility Criteria
You may qualify if:
- Genotype 1 hepatitis C infection (confirmed at screening)
- Patient has not received any prior treatment for hepatitis C
- Patient must have had a liver biopsy within 3 years before screening (or between the screening and baseline visit) showing chronic hepatitis C infection
- Must agree to use 2 forms of effective contraception throughout study (both males and females)
You may not qualify if:
- Infection with HIV or non genotype 1 hepatitis C
- Liver disease not related to hepatitic C infection
- Hepatic decompensation
- Significant laboratory abnormalities or other active diseases
- Pregnant or planning to become pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (62)
Unknown Facility
Dothan, Alabama, United States
Unknown Facility
Hoover, Alabama, United States
Unknown Facility
Phoenix, Arizona, United States
Unknown Facility
Bakersfield, California, United States
Unknown Facility
Coronado, California, United States
Unknown Facility
Long Beach, California, United States
Unknown Facility
San Diego, California, United States
Unknown Facility
Aurora, Colorado, United States
Unknown Facility
Englewood, Colorado, United States
Unknown Facility
Miami, Florida, United States
Unknown Facility
Chicago, Illinois, United States
Unknown Facility
Jackson, Mississippi, United States
Unknown Facility
Tupelo, Mississippi, United States
Unknown Facility
St Louis, Missouri, United States
Unknown Facility
New York, New York, United States
Unknown Facility
Chapel Hill, North Carolina, United States
Unknown Facility
Cincinnati, Ohio, United States
Unknown Facility
Philadelphia, Pennsylvania, United States
Unknown Facility
Nashville, Tennessee, United States
Unknown Facility
Dallas, Texas, United States
Unknown Facility
Houston, Texas, United States
Unknown Facility
San Antonio, Texas, United States
Unknown Facility
Darlinghurst, Australia
Unknown Facility
Fitzroy, Australia
Unknown Facility
Kingswood, Australia
Unknown Facility
Melbourne, Australia
Unknown Facility
Sydney, Australia
Unknown Facility
Wolloongabba, Australia
Unknown Facility
Calgary, Alberta, Canada
Unknown Facility
Ottawa, Ontario, Canada
Unknown Facility
Toronto, Ontario, Canada
Unknown Facility
Montreal, Quebec, Canada
Unknown Facility
Berlin, Germany
Unknown Facility
Heidelberg, Germany
Unknown Facility
Kiel, Germany
Unknown Facility
Tübingen, Germany
Unknown Facility
Guadalajara, Mexico
Unknown Facility
Mex Ctity, Mexico
Unknown Facility
Monterrey, Mexico
Unknown Facility
Auckland, New Zealand
Unknown Facility
Christchurch, New Zealand
Unknown Facility
Hamilton, New Zealand
Unknown Facility
San Juan, Puerto Rico
Unknown Facility
Bucharest, Romania
Unknown Facility
Moscow, Russia
Unknown Facility
Nizhny Novgorod, Russia
Unknown Facility
Saint Petersburg, Russia
Unknown Facility
Samara, Russia
Unknown Facility
Smolensk, Russia
Unknown Facility
Barcelona, Spain
Unknown Facility
Madrid, Spain
Unknown Facility
Seville, Spain
Unknown Facility
Valencia, Spain
Unknown Facility
Donetsk, Ukraine
Unknown Facility
Kiev, Ukraine
Unknown Facility
Kyiv, Ukraine
Unknown Facility
Vinnytsia, Ukraine
Unknown Facility
Derby, United Kingdom
Unknown Facility
Liverpool, United Kingdom
Unknown Facility
London, United Kingdom
Unknown Facility
Nottingham, United Kingdom
Unknown Facility
Plymouth, United Kingdom
Related Publications (2)
Lenz O, Verbinnen T, Fevery B, Tambuyzer L, Vijgen L, Peeters M, Buelens A, Ceulemans H, Beumont M, Picchio G, De Meyer S. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol. 2015 May;62(5):1008-14. doi: 10.1016/j.jhep.2014.11.032. Epub 2014 Nov 28.
PMID: 25445400DERIVEDJacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014 Aug 2;384(9941):403-13. doi: 10.1016/S0140-6736(14)60494-3. Epub 2014 Jun 4.
PMID: 24907225DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Global Clinical Development Manager
- Organization
- Jan-Cil France
Study Officials
- STUDY DIRECTOR
Janssen R&D Ireland Clinical Trial
Janssen R&D Ireland
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- GT60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 7, 2011
First Posted
February 4, 2011
Study Start
February 1, 2011
Primary Completion
January 1, 2013
Study Completion
January 1, 2013
Last Updated
June 4, 2014
Results First Posted
June 4, 2014
Record last verified: 2014-05